Search

Your search keyword '"Hyperkalemia -- Care and treatment"' showing total 9 results
Start Over Descriptor "Hyperkalemia -- Care and treatment" Publisher business wire, inc.
9 results on '"Hyperkalemia -- Care and treatment"'

1. New Interim, Real-World Data Provides Additional Insights on Hyperkalemia and Safety of Kerendia[R] (finerenone) for Patients with Chronic Kidney Disease Associated with Type 2 Diabetes

Subjects
Diabetes therapy -- Safety and security measures, Chronic kidney failure -- Care and treatment, Hyperkalemia -- Care and treatment, Type 2 diabetes -- Care and treatment, Business, Business, international, Kerendia (Medication)
Abstract

* Interim results from FINE-REAL, a prospective, observational study evaluating clinical characteristics and treatment patterns in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) treated with [...]

Published
2023

2. Premier Inc. Working with AstraZeneca to Reduce Hospitalizations of Patients with Hyperkalemia

Subjects
AstraZeneca Pharmaceuticals L.P., Hospital patients -- Care and treatment, Evidence-based medicine, Sodium zirconium cyclosilicate, Health care industry, Pharmaceutical industry, Hyperkalemia -- Care and treatment, Health care reform, Health care industry, Business, Business, international
Abstract

Nearly 370 Hospitals Have Signed on to Implement Evidence-Based Care Practices Including LOKELMA([R]) (sodium - zirconium cyclosilicate) CHARLOTTE, N.C. -- Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced [...]

Published
2020

3. ZS Pharma Completes $55 Million Financing to Advance Its Novel Investigational Treatment for Hyperkalemia

Subjects
Alta Partners, Liver diseases -- Care and treatment, Venture capital companies, Hyperkalemia -- Care and treatment, Business, Business, international
Abstract

COPPELL, Texas -- ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular, and liver disorders, today announced that it has completed a $55 million Series D financing. [...]

Published
2014

4. ZS Pharma Announces Positive Results From the Extended Treatment Phase of Its Phase 3 Trial of ZS-9 in Patients With Hyperkalemia

Subjects
Clinical trials, Liver diseases -- Care and treatment, Hyperkalemia -- Care and treatment, Pharmaceutical industry -- Company sales and earnings -- Product development, Company earnings/profit, Business, Business, international
Abstract

COPPELL, Texas -- ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced top-line results from the Extended Treatment Phase of ZS003, its [...]

Published
2014

5. ZS Pharma Announces Positive Top-Line Results of Phase 3 Trial of ZS-9 in Patients with Hyperkalemia

Subjects
Clinical trials, Liver diseases -- Care and treatment, Hyperkalemia -- Care and treatment, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

Phase 2 and Preliminary Phase 3 Data Presented During Late-Breaking Clinical Trial Oral Presentation at American Society of Nephrology's (ASN) Annual Scientific Meeting COPPELL, Texas -- ZS Pharma, a specialty [...]

Published
2013

7. Relypsa Enrolls Initial Patient in Pivotal Phase 3 Program for the Treatment of Hyperkalemia

Subjects
United States. Food and Drug Administration, Chronic kidney failure -- Care and treatment, Clinical trials, Hyperkalemia -- Care and treatment, Business, Business, international
Abstract

REDWOOD CITY, Calif. -- Relypsa, Inc., a clinical-stage biopharmaceutical company, announced that the first patient has been enrolled in the company's pivotal Phase 3 clinical study evaluating the efficacy and [...]

Published
2013

8. Relypsa Announces Agreement with FDA on Special Protocol Assessment for Patiromer Phase 3 Trial for the Treatment of Hyperkalemia

Subjects
United States. Food and Drug Administration, Chronic kidney failure -- Care and treatment, Clinical trials, Hyperkalemia -- Care and treatment, Business, Business, international
Abstract

-- According to data reported at Kidney Week 2012, an ongoing Phase 2b study of patiromer met the interim analysis primary endpoint of mean reduction in serum potassium after four [...]

Published
2013

9. Relypsa Begins Treatment in AMETHYST-DN Trial of RLY5016 for Hyperkalemia in Diabetic Nephropathy Patients with Chronic Kidney Disease

Subjects
Chronic kidney failure -- Care and treatment, Clinical trials, Hyperkalemia -- Care and treatment, Diabetic nephropathies -- Care and treatment, Business, Business, international
Abstract

SANTA CLARA, Calif. -- Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy [...]

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results